(Novartis (GNF) oral in vivo RET kinase inhibitor)
< 1 minute read
Sep. 15, 2021
WF-47-JS03: An oral in vivo RET kinase inhibitor
WF-47-JS03
RET kinase inhibitor orally efficacious in XG but narrow TI from data mining of internal matter and opt. ACS Med. Chem. Lett. Feb. 12, 2020 Novartis (GNF), San Diego, CA